A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A study that compares chemotherapy perioperatively (before and after surgery) versus adjuvant (only after surgery) for the treatment of pancreatic cancer that can be removed by surgery.
About
The primary objective of this study is to evaluate and compare overall survival (OS) in patients with resectable pancreatic adenocarcinoma treated with perioperative mFOLFIRINOX and surgery versus up-front surgery followed by adjuvant mFOLFIRINOX.
Eligibility Criteria
Inclusion Criteria
- 18 years or older
- Histologic or cytologic proof of pancreatic adenocarcinoma or adenosquamous carcinoma
- Staging: Tx-4, N0-1, M0
- Local radiographic reading consistent with resectable disease
- Determined to be an appropriate candidate for curative-intent pancreatectomy
- No prior radiation therapy, chemotherapy, targeted therapy, investigational therapy or surgery for pancreatic cancer
Exclusion Criteria
N/A
Primary Investigator
David Salzberg, MD, is a board-certified general and bariatric surgeon. He received his MD from the Medical College of Virginia in Richmond, VA. Dr. Salzberg completed both his general surgery residency and transplantation fellowship at MCV. He also completed a second fellowship in bariatric surgery and advanced minimally invasive surgery at the University of California. Dr. Salzberg joined the Department of General Surgery in 2016 and specializes in bariatric, hepatobiliary, transplant and esophageal surgeries. He is also an assistant professor at the Virginia Tech Carilion School of Medicine. Additionally, he serves as the director of both the Carilion Clinic Metabolic Center and the Carilion Clinic/Virginia Tech Biodesign Program.
Contact Information
Bailey Steele, MPH
Clinical Research Coordinator
